BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.

We investigated whether antisense oligodeoxynucleotides complementary to bcr/abl mRNA or protein kinase antagonists display antitumor activity on Ph1-positive leukemia cell lines. bcr/abl antisense oligomers showed inhibitory effects on the in vitro growth of Ph1-positive leukemia cell lines in liquid culture, and further displayed an inhibitory effect on transformed murine hematopoietic cells using transfection with a retroviral vector expressing P210bcr/abl oncoprotein. However, in vitro treatment with a bcr/abl antisense oligomer did not completely abolish the expression of bcr/abl mRNA and did not display the desired "killing effect" on Ph1-positive leukemia cells. On the other hand, investigation of the effect on Ph1-positive leukemia cells by various types of protein kinase antagonists revealed that herbimycin A, a protein tyrosine kinase antagonist, displays preferential and remarkable suppression of the growth of Ph1-positive leukemia cells and P210bcr/abl associated transformed cells by virtue of suppressing bcr/abl protein tyrosine kinase activity. These results may provide important future insights in developing a new category of antitumor therapy by targeting oncogene products.

[1]  T. Miyazaki,et al.  Inhibitory anti-tumor effects of interleukin-4 on Philadelphia chromosome-positive acute lymphocytic leukemia and other hematopoietic malignancies. , 1992, Leukemia & lymphoma.

[2]  T. Miyazaki,et al.  Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive , 1992, Blood.

[3]  M. Ratajczak,et al.  Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. , 1992, Blood.

[4]  M. Cazzola,et al.  c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers. , 1992, Leukemia.

[5]  Fukazawa Hidesuke,et al.  Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro , 1991 .

[6]  T. Miyazaki,et al.  Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells. , 1991, Blood.

[7]  B. Calabretta,et al.  Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. , 1991, Science.

[8]  C. Denny,et al.  Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines , 1991, Molecular and cellular biology.

[9]  B. Calabretta,et al.  Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Heisterkamp,et al.  Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. , 1991, Oncogene.

[11]  B. Dolnick.  Antisense agents in cancer research and therapeutics. , 1991, Cancer investigation.

[12]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Elefanty,et al.  bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. , 1990, The EMBO journal.

[14]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[15]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[16]  S. Mizuno,et al.  Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. , 1989, Biochemical and biophysical research communications.

[17]  S. Mizuno,et al.  Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1. , 1989, Cancer research.

[18]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Smith,et al.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Stein,et al.  Oligodeoxynucleotides as inhibitors of gene expression: a review. , 1988, Cancer research.

[21]  S. Mizuno,et al.  Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. , 1988, Virology.

[22]  A. Nienhuis,et al.  An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation , 1988, Molecular and cellular biology.

[23]  E. Wickstrom,et al.  Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  O. Witte,et al.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Groudine,et al.  Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells , 1987, Molecular and cellular biology.

[26]  R. Kurzrock,et al.  Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia , 1987 .

[27]  T. Miyazaki,et al.  Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia , 1987 .

[28]  A. Carè,et al.  Characterization of cDNA clones for human myeloperoxidase: predicted amino acid sequence and evidence for multiple mRNA species. , 1987, Nucleic acids research.

[29]  M. Greaves,et al.  A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia , 1987, Nature.

[30]  Y. Uehara,et al.  Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. , 1985, Japanese journal of cancer research : Gann.

[31]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[32]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[33]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[34]  E. Scolnick,et al.  Growth of factor-dependent hemopoietic precursor cell lines , 1980, The Journal of experimental medicine.

[35]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[36]  R. Schrek,et al.  Statistical Analysis of 2,407 Admissions to the Tumor Clinic of Veterans Hospital, Hines, Illinois, during 1943 , 1945 .